Phase 1 SRG-514 for Breast-Conserving Cancer Surgery - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called SRG-514 (the study drug) is a safe and effective option for breast cancer patients. We want to know if it can reduce the inflammation caused by surgery and allow your body to better heal itself and prevent tumor recurrence. We will also be trying to figure out the best dose of the drug to use.

What is the Condition Being Studied?

Breast Cancer

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with breast carcinoma or ductal carcinoma in situ
Plan to have breast-conserving surgical treatment
Do not have a diagnosis of inflammatory breast cancer

For more information, contact the study team at felecia.walton@duke.edu.

Age Group

Adults

What is Involved?

If you choose to join this study, the study drug will be placed directly into your breast in the area where your tumor is removed. You will need to return to Duke on days 1, 2, 7, 14, and 60 after your surgery for check-up visits with the study team.